U.S. Food And Drug Administration Approves Pfizer's XALKORI® (crizotinib) Posted: 28 Aug 2011 03:00 PM PDT  Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved XALKORI® (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test. |
Pharma News
Subscribe to:
Post Comments (Atom)
Thank you so much for sharing all this wonderful information! We hope you will sharing some more information, online pharmacy app development
ReplyDeleteonline pharmacy app development solution